中东和非洲生物仿制药市场预测至 2028 年 - COVID-19 影响和按疾病适应症(癌症、糖尿病、自身免疫性疾病和其他疾病)、药物类别(粒细胞集落刺激因子、人类生长激素、胰岛素、TNF 阻滞剂)进行的区域分析和单克隆抗体、促红细胞生成素刺激剂等)、给药途径(静脉内、皮下等)和最终用户(医院、专科诊所、家庭护理等)

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2028


No. of Pages: 158    |    Report Code: BMIRE00028364    |    Category: Life Sciences

Middle East & Africa Biosimilars Market

中东和中东地区非洲生物仿制药市场预计将从2022年的11.905亿美元增长到2028年的64.0887亿美元。预计2022年至2028年复合年增长率为32.4%。

生物仿制药和临床试验的合作正在推动中东和非洲的发展。非洲生物仿制药市场

合资企业和其他合作模式将帮助生物仿制药制造商在未来几年保持相对于市场竞争对手的竞争优势。通过与其他计划研究、推出和销售生物仿制药的公司合作,生物仿制药制造商可以快速开发产品并有效地推出产品,从而克服专利风险并赢得临床医生和患者对产品的信心。通过获得本地和国外的专业知识、开发平台访问以及研究和临床试验资金,可以加快产品开发。与更大的生物制药制造商合作可以使用现有的生产设施。这种合作可以针对外包活动,例如细胞系开发、生物制品和生物仿制药制造、工艺扩展以及任何所需的技术转让。合作可以带来长期利益。它们可以使国内未来生物仿制药生产项目的招标变得容易,并提供早期、高效的产品开发和市场渗透。生物仿制药市场的巨大潜力催生了许多近期备受瞩目的合作。因此,生物仿制药生产和临床试验制造商的合作将成为预测期内生物仿制药市场的主要趋势。

中东和中东地区非洲生物仿制药市场概览

中东和非洲生物仿制药市场分为沙特阿拉伯、南非、阿联酋和中东其他地区和非洲。该地区的市场增长归因于慢性病患病率的增加、政府的重大举措以及不断增加的产品开发正在推动生物仿制药市场的增长。

根据国际药物经济学和结果研究学会(ISPOR)预计,2020年,心血管疾病是沙特阿拉伯的首要死因,占所有死亡病例的45.7%。此外,由于生活方式的重大改变、不健康的饮食习惯和久坐的生活方式,沙特阿拉伯的糖尿病发病率正在上升。据IDF称,2021年,沙特阿拉伯的糖尿病发病率在8%至22%之间。糖尿病的主要因素是肥胖、不健康的生活方式、预期寿命的延长、医疗保健支出的增加和遗传易感性。据全国调查显示,2022年,沙特阿拉伯心血管疾病患病率为5.5%。因此,沙特阿拉伯因糖尿病病情上升而导致的心血管疾病增加正在推动生物仿制药市场的增长。

此外,沙特阿拉伯越来越多的生物仿制药产品批准正在推动生物仿制药市场的增长。沙特阿拉伯的生物仿制药市场。例如,沙特食品药品监督管理局 (SFDA) 已批准 Remsima 用于风湿病适应症,这是一种由 Celltrion 生产的英夫利昔单抗生物仿制药,并由当地公司 Jazeera Pharmaceutical Industries 获得许可。因此,日益增长的慢性病状况和主要参与者的产品主动性正在推动沙特阿拉伯生物仿制药市场的增长

中东和中东地区。到 2028 年非洲生物仿制药市场收入及预测(百万美元)

< span>

中东和中东地区非洲生物仿制药市场细分

中东和非洲非洲生物仿制药市场分为疾病适应症、药物类别、给药途径、最终用户和国家。

根据疾病适应症,生物仿制药市场分为癌症、糖尿病、自身免疫性疾病等疾病适应症。到 2022 年,癌症细分市场占据最大的市场份额。

生物仿制药市场根据药物类别分为粒细胞集落刺激因子、人类生长激素、胰岛素、TNF 阻滞剂和单克隆抗体、促红细胞生成素刺激剂等。 2022 年,粒细胞集落刺激因子细分市场占据最大份额。

根据给药途径,生物仿制药市场分为静脉注射、皮下注射和注射剂。其他的。到 2022 年,静脉注射细分市场将占据最大的市场份额。

生物仿制药市场根据最终用户细分为医院、专科诊所、家庭护理、和别的。到 2022 年,医院细分市场将占据最大的市场份额。

按国家/地区、中东和非洲地区划分。非洲生物仿制药市场分为沙特阿拉伯、南非、阿联酋以及中东和非洲其他地区。非洲。沙特阿拉伯将在 2022 年占据市场主导地位。

Amgen Inc; Sanofi SA;百康有限公司;礼来公司;山德士公司;梯瓦制药工业有限公司;辉瑞公司;和 Dr. Reddy\'s Laboratories Ltd 是在中东和非洲地区运营的领先公司。非洲生物仿制药市场。



Middle East & Africa Biosimilars Strategic Insights

Strategic insights for Middle East & Africa Biosimilars involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/middle-east-and-africa-biosimilars-market-strategic-framework.webp
Get more information on this report

Middle East & Africa Biosimilars Report Scope

Report Attribute Details
Market size in 2022 US$ 1,190.50 Million
Market Size by 2028 US$ 6,408.87 Million
Global CAGR (2022 - 2028) 32.4%
Historical Data 2020-2021
Forecast period 2023-2028
Segments Covered By 疾病适应症
  • 癌症
  • 糖尿病
  • 自身免疫性疾病
  • 其他疾病
By 药物类别
  • 粒细胞集落刺激因子
  • 人类生长激素
  • 胰岛素
  • TNF 阻滞剂和单克隆抗体
  • 促红细胞生成素刺激剂
By 给药途径
  • 静脉注射
  • 皮下注射
By 最终用户
  • 医院
  • 专科诊所
  • 家庭护理
Regions and Countries Covered 中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
Market leaders and key company profiles
  • Amgen Inc
  • Sanofi SA
  • Biocon Ltd
  • Eli Lilly and Co
  • Sandoz AG
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Dr. Reddys Laboratories Ltd
  • Get more information on this report

    Middle East & Africa Biosimilars Regional Insights

    The regional scope of Middle East & Africa Biosimilars refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/middle-east-and-africa-biosimilars-market-geography.webp
    Get more information on this report

    The List of Companies - Middle East & Africa Biosimilars Market

    1. Amgen Inc
    2. Sanofi SA  
    3. Biocon Ltd
    4. Eli Lilly and Co
    5. Sandoz AG
    6. Teva Pharmaceutical Industries Ltd
    7. Pfizer Inc
    8. Dr. Reddy's Laboratories Ltd
    Frequently Asked Questions
    How big is the Middle East & Africa Biosimilars Market?

    The Middle East & Africa Biosimilars Market is valued at US$ 1,190.50 Million in 2022, it is projected to reach US$ 6,408.87 Million by 2028.

    What is the CAGR for Middle East & Africa Biosimilars Market by (2022 - 2028)?

    As per our report Middle East & Africa Biosimilars Market, the market size is valued at US$ 1,190.50 Million in 2022, projecting it to reach US$ 6,408.87 Million by 2028. This translates to a CAGR of approximately 32.4% during the forecast period.

    What segments are covered in this report?

    The Middle East & Africa Biosimilars Market report typically cover these key segments-

  • 疾病适应症 (癌症, 糖尿病, 自身免疫性疾病, 其他疾病)
  • 药物类别 (粒细胞集落刺激因子, 人类生长激素, 胰岛素, TNF 阻滞剂和单克隆抗体, 促红细胞生成素刺激剂)
  • 给药途径 (静脉注射, 皮下注射)
  • What is the historic period, base year, and forecast period taken for Middle East & Africa Biosimilars Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Biosimilars Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2028
  • Who are the major players in Middle East & Africa Biosimilars Market?

    The Middle East & Africa Biosimilars Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Amgen Inc
  • Sanofi SA
  • Biocon Ltd
  • Eli Lilly and Co
  • Sandoz AG
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Dr. Reddys Laboratories Ltd
  • Who should buy this report?

    The Middle East & Africa Biosimilars Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Middle East & Africa Biosimilars Market value chain can benefit from the information contained in a comprehensive market report.